INTERVIEW WITH ALICIA MORGANS
Prostate Cancer Awareness Month September 2019 - US TOO SEA Blue Event

INTERVIEW WITH CHARLES RYAN
APCCC 2019 Global vs. Expert Consensus in the Management of Advanced Prostate Cancer Study

INTERVIEW WITH SILKE GILLESSEN & AURELIUS OMLIN
The Side Effects of Advanced Prostate Cancer Consensus Conference 2019 (APCCC)

INTERVIEW WITH JAMES GULLEY
Immunotherapy Across Genitourinary Malignancies

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

Intralesional Collagenase Clostridium Histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis.

In a multi-institutional setting we studied the efficacy and safety outcomes at multiple high volume centers where collagenase Clostridium histolyticum is used to treat Peyronie's disease.

We collected retrospective data on consecutive patients with Peyronie's disease who underwent treatment with collagenase C. histolyticum between April 2014 and March 2018 at a total of 5 institutions. Included in study were 918 patients. Main outcomes of interest included the change in curvature after receiving collagenase C. histolyticum therapy and the frequency of serious treatment related adverse events. The 2-tailed paired Student t-test was used to compare continuous variables. Univariate and multivariate regression analyses were performed to assess predictors of the success of collagenase C. histolyticum therapy to improve curvature.

In the cohort of 918 patients curvature improved from a mean of 48.2 degrees before treatment to 32.9 degrees after treatment, a 30.1% improvement from baseline (p <0.0001). Of the men 68.7% had a 20% or greater improvement in curvature. In the 502 patients who completed 4 or more cycles curvature improved from a mean of 49.7 degrees before to 32.7 degrees after treatment, a 33% improvement from baseline (p <0.0001). Of these men 74.4% experienced a 20% or greater improvement in curvature. A complication of treatment developed in 9% of patients. The number of cycles of collagenase C. histolyticum received was predictive of curvature improvement (p <0.0001).

This large multi-institutional analysis confirms the safety and efficacy of collagenase C. histolyticum therapy in men with Peyronie's disease. Intralesional collagenase C. histolyticum for Peyronie's disease according to the IMPRESS (Investigation of Maximal Peyronie's Reduction Efficacy and Safety Studies) trial protocol produced an improvement in penile curvature in men with Peyronie's disease with a low rate of complications.

The Journal of urology. 2019 Jan 18 [Epub ahead of print]

Wayne J G Hellstrom, Hoang Minh Tue Nguyen, Laith Alzweri, Amanda Chung, Ramón Virasoro, Ashley Tapscott, Matthew Ziegelmann, Landon Trost, Martin Gelbard

Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana., Department of Urology, Eastern Virginia Medical School, Norfolk, Virginia., Carolina Urology Partners, Huntersville, North Carolina., Department of Urology, Mayo Clinic, Rochester, Minnesota., Department of Urology, University of California-Los Angeles, Los Angeles, California.

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe